ALNY Alnylam Pharmaceuticals Inc

Price (delayed)

$147.5

Market cap

$17.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.49

Enterprise value

$18.28B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The gross profit has soared by 55% YoY and by 4.4% from the previous quarter
The company's revenue has surged by 54% YoY and by 4.2% QoQ
The debt has soared by 92% YoY
The equity has plunged by 57% YoY and by 32% from the previous quarter

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
120.81M
Market cap
$17.82B
Enterprise value
$18.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
44.2
Price to sales (P/S)
20.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.77
Earnings
Revenue
$879.98M
EBIT
-$739.36M
EBITDA
-$652.75M
Free cash flow
-$654.28M
Per share
EPS
-$7.49
Free cash flow per share
-$5.43
Book value per share
$3.34
Revenue per share
$7.31
TBVPS
$28.52
Balance sheet
Total assets
$3.43B
Total liabilities
$3.03B
Debt
$995.39M
Equity
$401.17M
Working capital
$1.98B
Liquidity
Debt to equity
2.48
Current ratio
4.27
Quick ratio
3.95
Net debt/EBITDA
-0.71
Margins
EBITDA margin
-74.2%
Gross margin
83.6%
Net margin
-101.5%
Operating margin
-76%
Efficiency
Return on assets
-25.4%
Return on equity
-137.4%
Return on invested capital
-24.8%
Return on capital employed
-26.1%
Return on sales
-84%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
0.82%
1 week
7.59%
1 month
16.1%
1 year
-15.07%
YTD
-13.02%
QTD
-9.67%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$879.98M
Gross profit
$735.27M
Operating income
-$669.13M
Net income
-$892.87M
Gross margin
83.6%
Net margin
-101.5%
The gross profit has soared by 55% YoY and by 4.4% from the previous quarter
The company's revenue has surged by 54% YoY and by 4.2% QoQ
The company's operating margin rose by 46% YoY and by 9% QoQ
The net margin has grown by 34% YoY

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
44.2
P/S
20.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.77
ALNY's EPS is down by 4% since the previous quarter
The equity has plunged by 57% YoY and by 32% from the previous quarter
ALNY's price to book (P/B) is 30% more than its last 4 quarters average of 34.1
ALNY's price to sales (P/S) is 71% lower than its 5-year quarterly average of 70.2 and 23% lower than its last 4 quarters average of 26.3
The company's revenue has surged by 54% YoY and by 4.2% QoQ

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
The ROE has plunged by 79% YoY and by 26% from the previous quarter
ALNY's return on sales is up by 37% year-on-year
ALNY's return on invested capital is up by 9% year-on-year
The return on assets has increased by 3.4% year-on-year but it has declined by 3.3% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 13% more than the total liabilities
The company's total liabilities rose by 30% YoY
Alnylam Pharmaceuticals's current ratio has decreased by 14% YoY but it has increased by 6% from the previous quarter
The debt is 148% more than the equity
The debt has soared by 92% YoY
The equity has plunged by 57% YoY and by 32% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.